We’re striving to make a difference for people impacted by #IBD. Learn how we’re working to reimagine the standards of care through innovation and research: https://abbv.ie/cb1af7 #UlcerativeColitis #CrohnsDisease [Image description: Roopal Thakkar, M.D., EVP, R&D, Chief Scientific Officer, AbbVie, says, "We are committed to strengthening our diversified inflammatory bowel disease (IBD) portfolio, providing healthcare professionals with more options to treat their IBD patients."]
Immunology
Pharmaceutical Manufacturing
AbbVie's deep expertise in immunology has been the result of our commitment to innovation and world-class science.
Über uns
Follow AbbVie's Immunology page for news and updates about chronic and progressive diseases in the field of immunology, including dermatology, gastroenterology and rheumatology.
- Website
-
https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology.html
External link for Immunology
- Industrie
- Pharmaceutical Manufacturing
- Größe des Unternehmens
- 10.001+ Mitarbeiter
Aktualisierungen
-
JUST IN: The European Medicines Agency approved our latest treatment for adults with moderately to severely active #UlcerativeColitis. Read more: https://bit.ly/3SpMKWF #IBD [Video description: On-screen text reads, “Immunology News. European Commission Approval in Ulcerative Colitis.”]
-
Celsius Therapeutics is now part of AbbVie. This #acquisition expands our pipeline with a novel approach in #IBD – because fueling scientific progress takes all of us. Learn more: https://bit.ly/3XI7w7d $ABBV [Video description: On-screen text reads, “Celsius is now part of AbbVie” followed by the AbbVie and Celsius logos.]
-
Reflecting on the data we presented at #EULAR2024, we remain dedicated to addressing some of the most difficult-to-treat rheumatic diseases to make a difference in patients' lives. Explore: https://bit.ly/3xh7xUU #Rheumatology [Video description: Tim Shaw, Therapeutic Area Head, Rheumatology, International Medical Affairs, AbbVie, says, “Congresses like EULAR enable us to engage with the rheumatology community and work together toward a common goal of improving life for patients living with rheumatic diseases.”]
-
The Global Alliance For Patient Access (GAfPA)’s new white paper on the value of remission in inflammatory rheumatic conditions, discussed during #EULAR2024, outlines that achieving remission is more than just symptom management – it’s also the ability of patients to lead fuller lives in every facet of their care. Click below to read more.
Today GAfPA launched a landmark report: The Value of Achieving Remission in Inflammatory Arthritis Evidence Glossary. The document provides for the first time a full picture of 🌍 the global clinical, social and economic impact of inflammatory rheumatic conditions 💙 the value of achieving remission for patient wellbeing. Learn more here: https://lnkd.in/dfDc2jcM #EULAR2024 #valueofremission #rheumaticcondition
-
-
At #EULAR2024, we’re presenting 25 abstracts showcasing data across our #rheumatology portfolio. Learn more about our commitment to delivering solutions for people with immune-mediated diseases: https://bit.ly/3XqF6hI [Video description: Sofie Berg, Pharm.D, Ph.D., Therapeutic Area Head, International Immunology, International Medical Affairs, AbbVie, says, “With our rich legacy and understanding of rheumatic diseases, I’m encouraged by the growing body of evidence and long-term data our teams are presenting at EULAR this year as we continue our efforts to advance research in this space.”]
-
#IBD is a complex set of diseases, meaning patients have diverse needs. Through ongoing research and development, we’re working to find solutions to help them manage their disease. Read how: https://bit.ly/3x1gRfq #UlcerativeColitis #Crohns [Image description: Sofie Berg, Pharm.D., Ph.D., Therapeutic Area Head, International Immunology, International Medical Affairs, AbbVie, says, “We are motivated to bring new treatment options to patients in need through our commitment to ongoing research and development in gastroenterology.”]
-
-
NEWS: The European Medicines Agency's #CHMP granted a positive opinion for our investigational treatment in #UlcerativeColitis. Read more: https://bit.ly/4bXADY2 #IBD [Video description: On-screen text reads, “Immunology News. Positive CHMP Opinion in Ulcerative Colitis.”]